Clinical trial research in focus: time to reflect on the design of exacerbation trials in COPD

Research output: Contribution to journalArticle


Exacerbations of respiratory symptoms occur frequently and are responsible for much of the morbidity associated with chronic obstructive pulmonary disease (COPD).1 Not all patients with COPD experience exacerbations, but some patients experience frequent exacerbations of their disease.2 One of the main goals of COPD management is to reduce exacerbations, and several drugs have been shown to reduce the number of exacerbations in patients at risk.1 Most of the evidence base for reducing the risk of exacerbations comes from carefully planned efficacy trials in narrowly defined populations, with the 2016 effectiveness trial, The Salford Lung Study, as a notable exception.

Bibliographical metadata

Original languageEnglish
Pages (from-to)466-468
Number of pages3
JournalThe Lancet Respiratory Medicine
Issue number6
Early online date26 May 2017
Publication statusPublished - Jun 2017